| 8:45:9:00 |
Introduction |
| 9:00-9:45 |
Keynote lecture: Therapeutic antibodies to harness tolerance mechanisms of the Immune System – Herman Waldmann (Oxford) |
| 9:45-10:05 |
From the lab to the market: actors, trends, stakeholders and the role of Aviesan – Marco Fiorini (Paris) |
|
Session1 : Tools, innovative technologies
|
| 10:05-10:45 |
Biological aspects
|
| 10:05-10:25 |
Anti-PCSK9 therapeutic antibodies – Catherine Boileau (Paris) |
| 10:25-10:45 |
Adipose derived stromal cells for osteoarthritis – Christian Jorgensen (Montpellier) |
| 10:45-11:15 |
Coffee break |
| 11:15-11:35 |
Embryonic stem cells and cardiac regeneration – Philippe Menasché (Paris) |
| 11:35-11:55 |
Fueling hematopoietic stem cell differentiation – Naomi Taylor (Montpellier) |
| |
Medical devices
|
| 11:15-12:15 |
Insulin pump becomes artificial pancreas – Eric Renard (Montpellier) |
| 12:15-12:35 |
Cartilage repair: current concepts – Didier Mainard (Nancy) |
| 12:35-12:55 |
Carmat total artificial heart – Christian Latrémouille (Paris) |
| |
|
| 12:55-14:05 |
Lunch buffet |
| |
|
| |
Session 2 : New preclinical trials models, animal model vs clinical
|
| 14:05-14:25 |
Genome editing with TALE and CRISPR/Cas9 nucleases – Carine Giovannangeli (Paris) |
| 14:25-14:45 |
Vagal stimulation for weight control – Charles-Henri Malbert (Rennes) |
| 14:45-15:05 |
Clinical trial methodology in chronic diseases: Reducing waste of research – Philippe Ravaud (Paris) |
| 15:05-15:25 |
Clinical trial in chronic hepatitis C – Patrick Marcellin (Paris) |
| 15:25-15:55 |
Coffee break |
| 15:55-16:35 |
Open innovation: the new model of Public Private Partnership / Sanofi – Isabelle Thizon De Gaulle (Paris) |
| 16:35-17:30 |
Round table - Therapeutic innovation
|
| |
Introduction – Renato Monteiro (Paris)
Drugs and Diagnostics based on the Gut Microbiome / ENTEROME (PME) – Pierre Belichard (Paris)
From basic research to industrial development : genesis of the biotech company HEMARINA – Franck Zal (Morlaix)
Inserm Transfert – Pascale Augé (Paris)
CEA Investissement – Célia Hart (Paris) |
| |
|
Friday, December 19th
|
| |
Session 3 : Biomarkers
|
| 9:00-9:20 |
Omics-based efficacy follow-up – Christophe Junot (Paris) |
| 9:20-9:40 |
Combination of genetic screening with platelet function testing for a personalized antiplatelet therapy – Jean-Sébastien Hulot (Paris) |
| 9:40-10:00 |
Genomics for adrenal tumors molecular markers development – Jérôme Bertherat (Paris) |
| 10:00-10:20 |
Pharmacokinetic-pharmacodynamic relationship (PK-PD) of therapeutic antibodies – Gilles Paintaud (Tours) |
| 10:20-10:40 |
Imaging biomarkers for the diagnosis of vulnerable atherosclerotic plaques – Alexis Broisat (Grenoble) |
| |
|
| 10:40-11:10 |
Coffee break |
| |
Session 4 : Local delivery
|
| 11:10-11:30 |
Cardiovascular biomaterials for controlled release – Didier Letourneur (Paris) |
| 11:30-11:50 |
Microparticles for controlled local drug delivery – Juergen Siepmann (Lille) |
| 11:50-12:10 |
Composite droplets: Delivering and creating drugs in-situ with an ultrasound scanner – Olivier Couture (Paris) |
| |
|
| 12:10-13:20 |
Lunch buffet |
| |
Session 5 : In silico investigation, bioinformatics, biostatistics, big data
|
| 13:20-13:40 |
in silico approaches to assist drug discovery – Bruno Villoutreix (Paris) |
| 13:40-14:00 |
Healthcare Information Systems: the challenges of semantic interoperability – Marie-Christine Jaulent (Paris) |
| 14:00-14:20 |
Big data & healthcare, new technologies can open the way to innovation / Orange Healthcare – Isabelle Hilali (Paris) |
| 14:20-14:40 |
Neuroimaging techniques for early diagnosis and prognosis : application to psychiatry - Fouad Hadj Selem |
| 14:40-15:00 |
Conclusion |
